Bristol/Gilead HIV Combo Will Go To FDA In Mid-2006
This article was originally published in The Pink Sheet Daily
Executive Summary
The combination of Bristol’s Sustiva and Gilead’s Truvada would be the first complete HAART regimen available as a single once-daily tablet.